Vu1 (VUOC) 10-K 30 Apr 15 2014 FY Annual report Financial data

DOCUMENT_AND_ENTITY_INFORMATIO

DOCUMENT AND ENTITY INFORMATION (USD $)	12 Months Ended
	Dec. 31, 2014	Apr. 16, 2015	Jun. 30, 2014
Document and Entity Information
Entity Registrant Name	Vu1 CORP
Entity Central Index Key	906448
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		14,173,093
Document Type	10-K
Amendment Flag	FALSE
Document Fiscal Period Focus	FY
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Public Float			$8,744,853

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash	$1,903	$92,795
Prepaid expenses	37,774	190,005
Total current assets	39,677	282,800
Non-current assets
Equipment, net of accumulated depreciation of $22,880 and $3,402	168,187	30,614
Total assets	207,864	313,414
Current liabilities
Accounts payable	1,441,178	1,148,368
Accrued payroll	192,725	192,725
Accrued interest	500,815	324,531
Judgment payable	1,295,920
Loan payable	100,000	100,000
Convertible debentures	2,788,300	3,905,975
Liabilities of Sendio	555,454	555,454
Total current liabilities	6,874,392	6,227,053
Total liabilities	6,874,392	6,227,053
Vu1 Corporation's stockholders' deficit
Preferred stock, $1.00 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, no par value; 90,000,000 shares authorized; 12,950,384 and 10,576,097 shares issued and outstanding, respectively	84,846,235	82,609,032
Accumulated deficit	-91,416,708	-88,426,616
Total Vu1 Corporation's stockholders' deficit	-6,570,473	-5,817,584
Non-controlling interest	-96,055	-96,055
Total stockholders' deficit	-6,666,528	-5,913,639
Total liabilities and stockholders' deficit	$207,864	$313,414

CONSOLIDATED_BALANCE_SHEETS_PA

CONSOLIDATED BALANCE SHEETS PARENTHETICAL (USD $)	Dec. 31, 2014	Dec. 31, 2013
CONSOLIDATED BALANCE SHEETS PARENTHETICAL
Accumulated depreciation	$22,880	$3,402
Preferred stock par value	$1	$1
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued
Preferred stock shares outstanding
Common stock par value
Common stock shares authorized	90,000,000	90,000,000
Common stock shares issued	12,950,384	10,576,097
Common stock shares outstanding	12,950,384	10,576,097

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating expenses
Research and development	$797,790	$646,611
General and administrative	1,143,154	1,692,010
Marketing	217,856	374,806
Total operating expenses	2,158,800	2,713,427
Loss from operations	-2,158,800	-2,713,427
Other income (expense)
Interest expense	-831,292	-1,191,786
Loss on conversion of debt		-1,114,764
Total other income (expense)	-831,292	-2,306,550
Loss before provision for income taxes	-2,990,092	-5,019,977
Provision for income taxes
Net loss	($2,990,092)	($5,019,977)
Loss per share
Loss per share - Basic	($0.26)	($0.55)
Loss per share - Diluted	($0.26)	($0.55)
Weighted average shares outstanding
Weighted average shares outstanding - Basic	11,413,406	9,144,940
Weighted average shares outstanding - Diluted	11,413,406	9,144,940

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Common Stock	Accumulated Deficit	Non-Controlling Interest	Total
Balance at Dec. 31, 2012	$78,279,737	($83,406,639)	($96,055)	($5,222,957)
Balance - Shares at Dec. 31, 2012	7,130,226
Share-based compensation - options	478,228			478,228
Share-based compensation - stock	631,139			631,139
Share-based compensation - stock - Shares	454,216
Issuance of units of stock and warrants for cash	1,503,465			1,503,465
Issuance of units of stock and warrants for cash - Shares	1,262,334
Issuance of stock and warrants for conversion of debenture	123,538			123,538
Issuance of stock and warrants for conversion of debenture - Shares	101,260
Issuance of stock and warrants for conversion of ST Debt	139,020			139,020
Issuance of stock and warrants for conversion of ST Debt - Shares	73,333
Amendment of Unit Offering - Shares	1,186,567
Issuance of stock and warrants for bridge note payable	1,453,905			1,453,905
Issuance of stock and warrants for bridge note payable - Shares	368,161
Net loss		-5,019,977		-5,019,977
Balance at Dec. 31, 2013	82,609,032	-88,426,616	-96,055	-5,913,639
Balance - Shares at Dec. 31, 2013	10,576,097
Share-based compensation - options	289,445			289,445
Share-based compensation - stock	207,587			207,587
Issuance of units of stock and warrants for cash	1,265,000			1,265,000
Issuance of units of stock and warrants for cash - Shares	1,850,000
Beneficial Conversion Feature	95,671			95,671
Interest converted to stock	245,300			245,300
Interest converted to stock - Shares	257,096
Bridge Loan and Interest Conversion	134,200			134,200
Bridge Loan and Interest Conversion - Shares	267,191
Net loss		-2,990,092		-2,990,092
Balance at Dec. 31, 2014	$84,846,235	($91,416,708)	($96,055)	($6,666,528)
Balance - Shares at Dec. 31, 2014	12,950,384

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net loss	($2,990,092)	($5,019,977)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation	19,479	3,402
Share-based compensation	497,032	1,109,367
Amortization of beneficial conversion feature	95,671
Amortization of discount on long-term convertible notes		571,254
Amortization of loan costs		118,500
Amortization of prepaid interest		25,000
Loss on extinguishment of debt		1,114,764
Changes in assets and liabilities:
Change in prepaid expenses	152,231	-172,283
Change in accounts payable	292,808	260,971
Change in accrued interest	851,681	272,396
Net cash flows from operating activities	-1,081,190	-1,716,606
Cash flows from investing activities:
Purchase of equipment	-157,052	-34,015
Net cash flows from investing activities	-157,052	-34,015
Cash flows from financing activities:
Net proceeds from sales of common stock and warrants	1,265,000	1,503,465
Payment on convertible debenture	-117,650	-88,237
Proceeds from loan payable	132,876	100,000
Payment on judgment payable	-132,876
Net cash flows from financing activities	1,147,350	1,515,228
Net change in cash	-90,892	-235,393
Cash, beginning of period	92,795	328,188
Cash, end of period	1,903	92,795
Supplemental Cash Flow Information:
Cash paid for interest	14,619
Supplemental Noncash Investing and Financing Activities:
Conversion of bridge loan and interest to stock	134,200
Issuance of common stock for interest	245,300
Conversion of debenture for stock		123,538
Conversion of bridge loan and interest to stock and warrants		1,453,905
Issuance of common stock and warrants for note payable and interest		$110,000

Note_1_Business_and_Organizati

Note 1 - Business and Organization	12 Months Ended
	Dec. 31, 2014
Notes
Note 1 - Business and Organization	NOTE 1 - BUSINESS AND ORGANIZATION
	General
	All references in these consolidated financial statements to “we,” “us,” “our,” and the “Company” are to Vu1 Corporation, Sendio, s.r.o., our former Czech Republic based subsidiary, and our inactive subsidiary Telisar Corporation, unless otherwise noted or indicated by its context.
	We are focused on designing, developing and selling a line of mercury free, energy efficient lighting products based on our proprietary light-emitting technology. For the past several years, we have primarily focused on research and development efforts for our technology and the related manufacturing processes.
	We have one inactive subsidiary, Telisar Corporation, a California corporation and 66.67% majority-owned subsidiary.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Notes
Note 2 - Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vu1 and all of its wholly-owned and controlled subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	For purposes of the statements of cash flows, we consider all investments purchased with original maturities of three months or less to be cash equivalents. At December 31, 2014 we have no cash in excess of federal insurance limits.
	Equipment
	Equipment is comprised of equipment used in the testing and development of the manufacturing process for our lighting products and is stated at cost. We provide for depreciation using the straight-line method over the estimated useful lives of three to five years. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains or losses on the sale of equipment are reflected in the statements of operations.
	Income Taxes
	We recognize the amount of income taxes payable or refundable for the current year and recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement amounts of certain assets and liabilities and their respective tax bases. Deferred tax assets and deferred tax liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled. A valuation allowance is required when it is less likely than not that we will be able to realize all or a portion of our deferred tax assets.
	FASB ASC 740-10-25 clarifies the accounting for uncertain tax positions and requires that an entity recognizes in the consolidated financial statements the impact of a tax position, if that position is more likely than not of being sustained upon examination, based on the technical merits of the position.  Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized tax benefits, if and when required, as part of income tax expense in the consolidated statements of operations.
	Long-Lived Assets
	Long-lived assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.  Management reviewed the assets at December 31, 2014 and determined there was no impairment.
	Fair Value of Financial Instruments
	Financial instruments consist of cash, payables and accrued liabilities, loans payable, bridge loans, judgment payable and convertible debentures. The fair value of our cash, receivables, payables and accrued liabilities, judgment payable and loans payable  are carried at historical cost; their respective estimated fair values approximate their carrying values due to the short term nature of these items. It is not practical to determine the fair value of our convertible debentures due to the unique terms and embedded financial instruments.
	Derivative financial instruments, as defined in ASC 815 “Accounting for Derivative Financial Instruments and Hedging Activities” consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g., interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. We generally do not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks.
	Fair Value Measurements
	ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. This hierarchy prioritizes the inputs into three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Significant fair value measurements resulted from the application of ASC 815 to our convertible promissory note and warrant financing arrangements and ASC 718-10 for our share-based payment arrangements.
	Non-Controlling Interest
	Non-controlling interest represents the equity of the 33.3% non-controlling shareholders of Telisar Corporation.  The subsidiary had no operations during 2014 and 2013.
	Revenue Recognition
	Revenues are recognized when (a) persuasive evidence of an arrangement exists, (b) delivery has occurred and no significant obligations remain, (c) the fee is fixed or determinable and (d) collection is determined to be probable.
	Research and Development Costs
	For financial reporting purposes, all costs of research and development activities performed internally or on a contract basis are expensed as incurred. For the years ended December 31, 2014 and 2013, research and development expenses were comprised primarily of technical consulting expenses, overheads, travel and operational costs related to the development of production.
	Share-Based Payments
	We account for share-based compensation expense to reflect the fair value of share-based awards measured at the grant date.  This expense is recognized over the requisite service period and is adjusted each period for anticipated forfeitures. We estimate the fair value of each share-based award on the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model incorporates assumptions as to stock price volatility, the expected life of options, a risk-free interest rate and dividend yield. On October 26, 2007 our Board of Directors approved the Vu1 Corporation 2007 Stock Incentive Plan (the “Stock Incentive Plan”).  A total of 500,000 shares of our common stock were authorized for issuance under the Stock Incentive Plan.  The Stock Incentive Plan was approved by our stockholders on May 22, 2008. On March 14, 2011, our Board of Directors increased the number of shares of our common stock that we are authorized to issue under our Stock Incentive Plan from 500,000 shares to 1,000,000 shares.  A majority of our stockholders approved the amendment to the Stock Incentive Plan on October 10, 2011. On August 26, 2013 the board of directors increased the number of shares authorized for issuance under the 2007 Stock Incentive Plan by 1,500,000 shares to a total of 2,500,000 shares. See Note 9.
	Loss Per Share
	We calculate basic loss per share by dividing loss available to common stockholders by the weighted-average number of shares of common stock outstanding, excluding unvested stock. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common shares, including unvested stock, had been issued and if the additional common shares were dilutive.
	The following potentially dilutive common shares are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to our net losses:
		Year ended December 31,
		2014	2013
	Warrants	6,622,228	4,772,228
	Convertible debt	1,304,631	1,152,223
	Stock options	829,936	595,088
	Unvested stock	-	319,231
	Total potentially dilutive securities	8,756,795	6,838,770
	Recently Announced Accounting Standards – In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. ASU 2014-09 will be effective for the Company’s fiscal year beginning January 1, 2017, with early application not permitted. The Company does not anticipate the adoption of ASU 2014-09 will have a material impact on its financial statements and related disclosures.
	In June 2014, the FASB issued ASU 2014-12, Compensation-Stock Compensation (Topic 718). The ASU clarifies how entities should treat performance targets that can be achieved after the requisite service period of a share-based payment award. The accounting standard is effective for interim and annual periods beginning December 15, 2015.  The Company does not anticipate the adoption of ASU 2014-12 will have a material impact on its financial statements and related disclosures.
	Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company’s financial position, result of operations or cash flows.

Note_3_Going_Concern_Matters

Note 3 - Going Concern Matters	12 Months Ended
	Dec. 31, 2014
Notes
Note 3 - Going Concern Matters	NOTE 3 - GOING CONCERN MATTERS
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States which contemplate our continuation as a going concern. For the year ended December 31, 2014, we had a net loss of $2,990,092 and we had negative cash flows from operations of $1,081,190. In addition, we had an accumulated deficit of $91,416,708 at December 31, 2014. In addition, in April, 2015 certain judgment holders placed a levy on all of our intellectual property, demanding that we turn over our patents, trade secrets, manufacturing methods and other intellectual property as discussed in Note 5. These factors raise substantial doubt about our ability to continue as a going concern.
	Recovery of our assets is dependent upon future events, the outcome of which is indeterminable. Our attainment of profitable operations is dependent upon obtaining adequate financing and achieving a level of sales adequate to support our cost structure. In addition, realization of a significant portion of the assets in the accompanying balance sheet is dependent upon our ability to meet our financing requirements and the success of our plans to sell our product. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should we be unable to continue in existence.
	Subsequent to year end through April 16, 2015, we raised gross proceeds of $260,000 in a private placement of our common stock and warrants to accredited investors.  See Note 12.

Note_4_Related_Party_Transacti

Note 4 - Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Notes
Note 4 - Related Party Transactions	NOTE 4 - RELATED PARTY TRANSACTIONS
	There were no related party transactions for the year ended December 31, 2014.
	During the year ended December 31, 2013 we issued 48,842 shares of common stock with a fair value of $75,000 to SAM Advisors, LLC. The issuances were based on the closing market prices as of the date of issuance pursuant to our agreement to convert their $12,500 monthly consulting fee to stock at the closing market price on the last business day of each month. SAM Advisors, Inc. is an entity controlled by William B. Smith, our chairman and chief executive officer.
	During the year ended December 31, 2013 we issued 6,143 shares of common stock with a fair value of $11,250 to Charles Hunt, a member of our board of directors. The issuances were based in the closing market prices as of the date of issuance pursuant to our agreement to convert $3,750 of his monthly consulting fee to stock at the closing market price on the last business day of each month.
	See also Note 7 – Convertible Bridge Loans

Note_5_Commitments_and_Conting

Note 5 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Notes
Note 5 - Commitments and Contingencies	NOTE 5 - COMMITMENTS AND CONTINGENCIES
	Judgments Payable
	On April 10, 2014 we received notice from one of the holders of our Convertible Debentures regarding a judgment they obtained on March 6, 2014 in the amount of $132,876, including principal of $117,650, accrued interest of $14,619 and costs of $607 as of that date. The judgment bore interest at a 9% rate until paid in full and is secured by the assets of the Company. On May 12, 2014 the judgment was paid in full.
	On June 11, 2014, four holders of our Convertible Debentures totaling $705,900 in principal plus accrued interest of $218,215 as of December 31, 2014 filed a motion seeking summary judgment with the Supreme Court of the State of New York.  The case was heard on July 31, 2014 and the court granted their request and on August 20, 2014 issued a judgment in their favor for the full amount of principal and interest, plus certain expenses.  We have made attempt to work with the judgment holders and their attorney to attempt to find a settlement agreeable to both parties, but no agreement has been reached. The judgment holders have the right to levy the judgment on our bank accounts, intellectual property and patents and other assets at any time. In April, 2015 the judgment holders placed a levy on all of our intellectual property, demanding that we turn over our patents, trade secrets, manufacturing methods and other intellectual property. The principal and accrued interest have been reclassified on the balance sheet from Convertible Debentures and accrued interest to Judgment payable on the accompanying balance sheet at December 31, 2014.
	On December 22, 2014, one of the holders of our Convertible Debentures totaling $294,125 plus accrued interest and costs of $77,680 obtained a judgment in their favor for the full amount of principal, interest and costs.  The principal and accrued interest have been reclassified on the balance sheet from Convertible Debentures and accrued interest to Judgment payable on the accompanying balance sheet at December 31, 2014.
	Operating Leases
	On January 28, 2014 we entered into a lease agreement for approximately 4,600 square feet of office and light industrial space located in Berkeley, California in the United States.  We utilize the facility for our research and development activities and as our corporate headquarters.
	The lease term is for two years effective from February 1, 2014 and terminates on January 31, 2016. Our remaining lease obligations are $60,000 and $5,000 for the years ended December 31, 2015 and 2016, respectively.  The Company is also responsible for certain insurance, utilities, maintenance and other costs as described in the lease.
	On December 18, 2012 we entered into a 6 month lease for office space in New York, New York. This lease was extended to December 31, 2013 on the same terms. Monthly rental payments were $2,035.  The lease was terminated by its terms as of that date.
	Total rent expense was $55,000 and $24,647 for the years ended December 31, 2014 and 2013, respectively.
	Liabilities of Sendio
	In September 2007, we formed Sendio, s.r.o. (“Sendio”) in the Czech Republic as a wholly-owned subsidiary for the purpose of operating a research and development and pilot manufacturing facility. On February 13, 2012, Sendio filed a petition of insolvency with the Regional Court in Olomouc, Czech Republic.  In March, 2012 the court determined that Sendio was insolvent, and control of the legal entity passed to a court appointed trustee. The trustee will oversee the orderly sale of the assets and use any proceeds to satisfy the liabilities of Sendio.  These liabilities have been recorded as a current liability on our balance sheet as of December 31, 2014 and December 31, 2013 under the caption “Liabilities of Sendio.”

Note_6_Convertible_Debentures

Note 6 - Convertible Debentures	12 Months Ended
	Dec. 31, 2014
Notes
Note 6 - Convertible Debentures	NOTE 6 – CONVERTIBLE DEBENTURES
	On June 22, 2011, pursuant to a Securities Purchase Agreement, dated as of June 16, 2011, with several institutional investors, we completed a private placement of our original issue discount convertible debentures (referred to as the convertible debentures), receiving gross proceeds of $3,500,000.  Each convertible debenture was issued at a price equal to 85% of its principal amount.  The convertible debentures matured on June 22, 2013, two years after the date of their issuance and did not bear regularly scheduled interest.  Investors may convert their convertible debentures into shares of our common stock at any time and from time to time on or before the maturity date, at a conversion price of $11.00 per share.
	The convertible debentures will mandatorily convert at our option into shares of our common stock at the conversion price, if the closing bid price for the common stock exceeds $30.00 per share for a period of 10 consecutive trading days, provided that such underlying shares have been fully registered for resale with the U.S. Securities and Exchange Commission (SEC).
	The convertible debentures are unsecured, general obligations of our company, and rank pari passu with our other unsecured and unsubordinated liabilities.  The convertible debentures are not redeemable or subject to voluntary prepayment by us prior to maturity.  The convertible debentures were identical for all of the investors except for principal amount.
	The investors agreed not to convert their convertible debentures or exercise their warrants, and we will not be permitted to require a mandatory conversion, to the extent such conversion, exercise or issuance would result in beneficial ownership of more than 4.99% of our outstanding shares at such time.
	Events of default under the convertible debentures include:
	•              failure to pay principal or any liquidated damages on any convertible debenture when due;
	•              failure to perform other covenants under the convertible debentures that is not cured five trading days after notice by holders;
	•              default under the other financing documents, subject to any grace or cure period provided in the applicable agreement, document or instrument;
	•              certain events of bankruptcy or insolvency of our company or any significant subsidiary.  The lender has waived this event of default with respect to the insolvency of Sendio.
	•              any default by our company or any subsidiary under any instrument in excess of $150,000 that results in such obligation becoming due and payable prior to maturity;
	•              we become party to a change of control transaction, or dispose of greater than 50% of our assets; and
	•              failure to deliver common stock certificates to a holder prior to the tenth trading day after a convertible debenture conversion date.
	Upon an event of default, the outstanding principal amount of the convertible debentures, plus a default premium, shall become immediately due and payable to the holders of the convertible debentures.
	The convertible debentures contain various covenants that limit our ability to:
	•              incur additional indebtedness, other than permitted indebtedness as defined in the convertible debenture;
	•              incur specified liens, other than permitted liens as defined in the convertible debenture;
	•              amend our certificate of incorporation or by-laws in a material adverse manner to the holders; and
	•              repay or repurchase more than a de minimus number of shares of our common stock.
	As part of the financing, we also agreed not to undertake a reverse or forward stock split or reclassification of our common stock until the one-year anniversary of the closing date, except with the consent of a majority in interest of the holders or in connection with an up-listing of our common stock onto a trading market other than the OTC Bulletin Board.
	We also issued to the investors five-year warrants to purchase up to 187,175 shares of our common stock at an exercise price of $13.00 per share.  The warrants may be exercised on a cashless basis at any time after the earlier of (i) one year after the date of their issuance or (ii) the completion of the applicable holding period required by Rule 144 in the event the underlying shares have not been fully registered for resale with the SEC.  The warrants are not callable.  Neither the warrants nor the convertible debentures contain a provision for anti-dilution adjustments in the event of a subsequent equity financing at a price less than the respective warrant exercise price or convertible debenture conversion price.
	Pursuant to a Registration Rights Agreement, dated as of June 16, 2011, with the investors, we agreed to file a shelf registration statement covering the resale of the shares of common stock issuable upon the conversion of the convertible debentures and exercise of the warrants within 30 days after the closing, use our best efforts to cause the shelf registration statement to be declared effective within 90 days after the closing (or 120 days in the event of a “full review” by the SEC), and keep the shelf registration statement effective until the underlying shares have been sold or may be sold without volume or manner of sale restrictions pursuant to Rule 144 under the Securities Act of 1933 and if we are unable to comply with this covenant, we will be required to pay liquidated damages to the investors in the amount of 1.5% of the investors’ purchase price per month during such non-compliance (capped at a maximum of 10% of the purchase price), with such liquidated damages payable in cash.  We filed the registration statement on July 15, 2011 and it was declared effective on July 26, 2011.  We evaluated any liability under the registration rights agreement at December 31, 2014 and determined no accrual was necessary.
	Effective June 22, 2013, the Company entered into a letter agreement with holders of $2,553,000 in principal amount of the Debentures.  The maturity date of these Debentures was extended to June 23, 2014 and the conversion price was reduced from $11.00 to $2.50 per share.  In addition, these Debentures will bear interest at an annual rate of 10% per annum, payable in equal installments on the six month and one year anniversary of the letter agreement.
	Also, effective June 22, 2013, the Company entered into a separate letter agreement with the holder of approximately $123,538 in principal amount of the Debentures to reduce the conversion price of these Debentures from $11.00 to $1.22 per share.  This holder then converted the principal amount of their Debentures into 101,260 shares of common stock.
	On June 20, 2014, we entered into a letter agreement with a Debenture holder of the original principal sum of $2,353,000.  Pursuant to the letter agreement, the Company and the holder agreed to extend the maturity date of the Debenture to June 22, 2015 and reduce the conversion price under the Debenture to $2.00 per share from the current $2.50 per share.  Additionally, we issued 125,160 shares of our common stock to the holder in payment of accrued, unpaid interest of $117,650 under the Debenture for the period from December 23, 2013 to June 22, 2014, which shares were valued at the closing price of $0.94 per share on the date of the agreement. On December 22, 2014 we issued 117,650 shares at a price of $1.00 per share of the Company's common stock to the holder in payment of accrued, unpaid interest of $117,650 under the Debenture for the period from June 23, 2014 to December 22, 2014. In April, 2015 we entered into an additional letter agreement to further amend the Debenture with the holder as discussed in Note 12.
	On October 24, 2014, we entered into a letter agreement with a Debenture holder of the original principal sum of $200,000.  Pursuant to the letter agreement, the Company and the holder agreed to extend the maturity date of the Debenture to June 22, 2015 and reduce the conversion price under the Debenture to $2.00 per share from the current $2.50 per share.  Additionally, we issued 14,286 shares of our common stock to the holder in payment of accrued, unpaid interest of $10,000 under the Debenture for the period from December 23, 2013 to June 22, 2014, which shares were valued at the closing price of $0.70 per share on the date of the agreement.
	We evaluated the amended debentures above to determine if there was an extinguishment of debt or beneficial conversion feature arising as a result of the amendments and determined there was none.
	On June 22, 2013, the Company did not make the required payment on the remaining $1,441,213 in principal amount of the Debentures described above, which constitutes an event of default under the terms of the remaining original Debentures.  As a result, the Company recorded a penalty of 10% of the principal amount of $144,121 as interest expense on the accompanying statement of operations for the year ended December 31, 2013. The Company is also liable for all other amounts, costs, expenses and liquidated damages due in respect of those Debentures.  Additionally, the remaining original Debentures will bear default interest at a rate of 18% per annum. As a result of the Debentures being past due, the investors may at any time exercise their remedies under the terms of the Debentures.
	The carrying value at December 31, 2014 and 2013 of the convertible debentures is as follows:
		31-Dec-14	31-Dec-13
	Debentures Due June 22, 2013, in default, interest at 18%	$            235,300	$         1,352,975
	Debentures Due June 22, 2015, interest at 10%	2,553,000	2,553,000
	Carrying value	$        2,788,300	$        3,905,975
	The original issue discount of the convertible debentures was amortized over their two-year life using the effective interest method.
	The proceeds were first allocated between the convertible debentures and the warrants based upon their relative fair values. The estimated fair value of the warrants issued with the convertible debentures of $1,018,582 was calculated using the Black-Scholes option pricing model and the following assumptions: market price of common stock – $9.00 per share; estimated volatility – 84.6%; risk-free interest rate – 1.58%, expected dividend rate – 0% and expected life – 5.0 years. This resulted in allocating $788,972 to the warrants and $2,711,028 to the convertible debentures.
	Next, the intrinsic value of the beneficial conversion feature was computed as the difference between the fair value of the common stock issuable upon conversion of the convertible debentures and the total price to convert based on the effective conversion price. This resulted in allocating $658,840 to the beneficial conversion feature. The resulting $1,447,812 discount to the convertible debentures is being amortized over the two-year term of the convertible debentures using the effective interest method.
	In conjunction with the placement of the convertible debentures, we paid our investment banker $245,000 as a placement fee and issued five-year warrants to purchase 26,205 shares of our common stock at an exercise price of $13.00 per share.  All terms are identical to the warrants issued to the holders of the convertible debentures. The estimated fair value of the warrants issued with the convertible debentures of $142,601 was calculated using the Black-Scholes option pricing model and the following assumptions: market price of common stock – $9.00 per share; estimated volatility – 84.6%; risk-free interest rate – 1.58%, expected dividend rate – 0% and expected life – 5.0 years.  In addition, we incurred legal and other costs of $53,500 paid in cash.  These costs, totaling $441,101 were recorded as loan costs on the accompanying balance sheet on the date of issuance and were amortized to interest expense using the straight line method, which approximates the effective interest method, over the two-year term of the convertible debentures.
	Interest expense related to the convertible debentures is as follows:
		Year ended December 31,
		2014	2013
	Amortization of original issue discount	$                            -	$               155,443
	Amortization of beneficial conversion feature and warrant allocation	-	415,811
	Amortization of loan costs	-	104,392
	Penalty interest payable in cash	-	144,121
	Stated interest payable in cash	394,395	259,168
		$                  394,395	$             1,078,935

Note_7_Convertible_Bridge_Loan

Note 7 - Convertible Bridge Loans	12 Months Ended
	Dec. 31, 2014
Notes
Note 7 - Convertible Bridge Loans	NOTE 7 – CONVERTIBLE BRIDGE LOANS
	In October and November 2011, we received $475,000 in gross proceeds from six existing stockholders in an interim bridge loan financing involving the issuance of 12% convertible promissory notes and warrants to purchase common stock.  Included in the proceeds was $50,000 received from Mark W. Weber, a  related party and a member of our board of directors.  Under the notes, the loans are due upon the earlier of (a) the closing of financing pursuant to which shares of common stock or other equity securities are issued by us for aggregate consideration of not less than $5,000,000, through the (i) conversion of the note, including accrued interest, or (ii) at the lender’s option, repayment of the note, or (b) in any event, two years after the issuance of the note.  The number of shares of common stock issuable upon conversion of the note will be based on a conversion price equal to a 15% discount to the price obtained in any round of equity financing.  In the event we fail to repay the promissory notes on or before November 30, 2011, the note’s interest rate will be increased to 15% per annum.  We did not pay the promissory notes prior to that date, and the interest rate was increased to 15% per annum.
	Total interest expense relating to the loans described above for the year ending December 31, 2013 was $7,027.
	In addition to interest on the promissory note, each note holder received a warrant to purchase the number of shares of common stock determined by dividing 115% of the principal amount of the note by the price at which our common stock is sold in any round of equity financing not less than $5,000,000, times 100%.  The warrants will be exercisable at any time, commencing 90 days after the closing of the round of financing, and from time to time for a period of three years after the issuance date, at an exercise price of $11.00 per share (subject to appropriate adjustment in the event of any subsequent stock split or similar transaction).
	During February, 2013 three of the convertible bridge loans totaling $368,162 (including accrued interest and loan fees of $68,162) were converted into 368,162 shares of our restricted common stock, three year warrants to purchase 368,162 shares of our common stock at an exercise price of $1.50 per share and three year warrants to purchase 98,571 shares of our common stock at an exercise price of $11.00 per share.  The fair value of the common stock was $662,690 based on the market prices of our common stock on the date of conversion of $1.80 per share.  The fair value of the three year warrants to purchase 368,162 shares of our common stock at an exercise price of $1.50 per share was $633,121 and fair value of the three year warrants to purchase 98,571 shares of our common stock at an exercise price of $11.00 per share was $158,094.  We recognized a loss on debt conversion for the year ended December 31, 2013 in the amount of $1,085,744.
	The fair value of the warrants issued upon the conversions in 2013 was computed using the Black Scholes Option Pricing model using the following assumptions – expected life – 3 years, risk free interest rate – 0.82%, volatility – 227.1%, and an expected dividend rate of 0%.

Note_8_Loans_Payable

Note 8 - Loans Payable	12 Months Ended
	Dec. 31, 2014
Notes
Note 8 - Loans Payable	NOTE 8 – LOANS PAYABLE
	On December 20, 2012, we received gross proceeds of $100,000 pursuant to the terms of a Loan Agreement dated December 20, 2012.  The loan is secured by a deed of assignment for certain future inventory and proceeds from the sale of that inventory as described in the deed of assignment.  The loan was payable on June 23, 2013, six months from the date of the agreement.  We prepaid interest of $25,000 for the term of the loan and $15,000 for loan costs, which were amortized over the life of the note.  We recognized $339,900 and $81,714 of interest expense and $0 and $23,514 for loan cost amortization within interest expense for the years ended December 31, 2014 and 2013, respectively.
	On June 23, 2013 we did not repay the loan and it is in default.  As a result of the default, the interest rate on the loan is 109.5% per annum from the date of default.  The interest each month is accumulated and becomes part of the loan balance for the following month.  Effective January 20, 2015 the holders of these notes converted the outstanding balance of principal and accrued interest into shares of our common stock and warrants to purchase common stock. See Note 12. «AGJPWCCD»
	Total principal payments for future years for the Convertible Bridge Loans, the Convertible Debentures described in Note 6, the Convertible Bridge Loans described in Note 7 and the Loan Payable are as follows as of December 31, 2014:
		31-Dec-14
	2015	2,888,300
		$       2,888,300
	On May 9, 2014 we issued an unsecured Convertible Promissory Note for cash to an accredited investor in the amount of $132,876.  The note bears interest at an annual rate of 7% per year, payable on the six month and one year anniversary of the note. The interest is payable at the option of the Company in either cash or shares of common stock at the market price on the interest payment dates as defined in the note. The note is convertible at any time at the option of the holder at a rate of $0.50 per share into 265,751 shares of our common stock.  We evaluated the Note and determined it had a beneficial conversion feature due to the conversion price being lower than the market price of our common stock of $0.86 per share on the date of issuance.  Accordingly, we recognized a discount related to the beneficial conversion feature associated with the Note in the amount of $95,671 for the year ended December 31, 2014.
	On June 30, 2014 the holder of the note converted the principal amount by its terms into 265,751 shares of common stock.  In addition, the Company issued 1,440 shares of common stock related to the accrued interest of $1,325 based on the market price on the date of conversion of $0.92 per share.
	We recognized interest expense, comprised of $1,325 related to the stated interest rate of the note and $95,671 related to the beneficial conversion feature for the year ended December 31, 2014.
	On May 16, 2013 we received gross proceeds of $100,000 pursuant to a Loan Agreement as of that date.  The term of the loan was for 30 days.  Total interest for the 30 day term was $10,000, which was recognized as interest expense for the year ended December 31, 2013.  On June 18, 2013 the holder of the loan converted $110,000 of principal and interest in our unit private placement as further described in Note 9 at a conversion price of $1.50 per share into 73,333 shares of common stock and three-year warrants to purchase common stock at an exercise price of $2.00 per share.  The fair value of the common stock was $95,333 based on the market prices of our common stock on the date of conversion of $1.30 per share.  The fair value of the three year warrants to purchase 73,333 shares of our common stock at an exercise price of $2.00 per share was $43,687. We recognized a loss on conversion of debt for the year ended December 31, 2013 in the amount of $29,020.
	The fair value of the warrants issued upon the conversion was computed using the Black Scholes Option Pricing model using the following assumptions – expected life – 3 years, risk free interest rate – 0.42%, volatility – 91.4%, and an expected dividend rate of 0%.

Note_9_Stockholders_Equity

Note 9 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Notes
Note 9 - Stockholders' Equity	NOTE 9 - STOCKHOLDERS’ EQUITY
	Preferred Stock
	Our Amended and Restated Articles of Incorporation allow us to issue up to 10,000,000 shares of preferred stock without further stockholder approval and upon such terms and conditions, and having such rights, preferences, privileges, and restrictions as the Board of Directors may determine.  No preferred shares are currently issued and outstanding.
	Common Stock Issuances
	2014 Unit Offerings
	From January 31, 2014 to July 10, 2014 we received gross proceeds of $680,000 from accredited investors at a price of $1.00 per unit and issued 680,000 shares of common stock and two-year warrants to purchase 680,000 shares of common stock at an exercise price of $1.25 per share.
	The net proceeds of $680,000 were allocated based on the relative fair values of the common stock and the warrants on the dates of issuance.  The amount allocated to the fair value of the warrants was $182,473 and the balance of the proceeds of $497,527 was allocated to the common stock.  The fair value of the warrants issued was computed using the Black Scholes Option Pricing model using the following assumptions – expected life – 2 years, risk free interest rate – 0.31% to 0.52%, volatility – 76.7% to 97.4%, and an expected dividend rate of 0%.
	From August 4 to December 17, 2014 we received gross proceeds of $585,000 from accredited investors at a price of $0.50 per unit and issued 1,170,000 shares of common stock and two-year warrants to purchase 1,170,000 shares of common stock at an exercise price of $0.75 per share.
	The net proceeds of $585,000 were allocated based on the relative fair values of the common stock and the warrants on the dates of issuance.  The amount allocated to the fair value of the warrants was $221,133 and the balance of the proceeds of $363,867 was allocated to the common stock.  The fair value of the warrants issued was computed using the Black Scholes Option Pricing model using the following assumptions – expected life – 2 years, risk free interest rate – 0.41% to 0.64%, volatility – 83.9% to 201.8%, and an expected dividend rate of 0%.
	2013 Unit Offerings
	On January 25, 2013 we completed a private placement to accredited investors of 105,000 restricted shares of our common stock, at a purchase price of $1.00 per share, for gross proceeds of $105,000.  As part of the private placement, the investors were issued three-year warrants to purchase 105,000 shares of our common stock, at an exercise price of $1.50 per share.
	The net proceeds were allocated based on the relative fair values of the common stock and the warrants on the dates of issuance.  The amount allocated to the fair value of the warrants was $52,363 and the balance of the proceeds of $52,637 was allocated to the common stock.
	The fair value of the warrants issued in our unit private placement was calculated using the Black-Scholes option valuation model with the following assumptions – expected life – 3 years, risk free interest rate – 0.42%, volatility – 346.4%, and an expected dividend rate of 0%.
	From April 9 to July 11, 2013 we raised gross proceeds of $871,000 in a unit private placement to accredited investors at a price of $1.50 per unit.  Each unit is comprised of one share of common stock and one three-year warrant to purchase common stock at an exercise price of $2.00 per share.  Included in the proceeds is $110,000 of principal and interest which was converted into the unit offering as described in Note 9.  Also included is $10,000 received from a member of our board of directors.  We issued an aggregate of 580,667 shares of common stock and warrants to purchase 580,667 shares of common stock at an exercise price of $2.00 per share.
	The net proceeds of $761,000 were allocated based on the relative fair values of the common stock and the warrants on the dates of issuance.  The amount allocated to the fair value of the warrants was $256,836 and the balance of the proceeds of $504,164 was allocated to the common stock.  The fair value of the warrants issued was computed using the Black Scholes Option Pricing model using the following assumptions – expected life – 3 years, risk free interest rate – 0.34% to 0.65%, volatility – 91.4% to 150.3%, and an expected dividend rate of 0%.
	From October 10 to December 31, 2013 we received gross proceeds of $650,000 from accredited investors at a price of $1.00 per unit and issued 650,000 shares of common stock and two-year warrants to purchase 650,000 shares of common stock at an exercise price of $1.25 per share.
	The net proceeds of $650,000 were allocated based on the relative fair values of the common stock and the warrants on the dates of issuance.  The amount allocated to the fair value of the warrants was $256,836 and the balance of the proceeds of $504,164 was allocated to the common stock.  The fair value of the warrants issued was computed using the Black Scholes Option Pricing model using the following assumptions – expected life – 2 years, risk free interest rate – 0.28% to 0.38%, volatility – 81.5% to 113.0%, and an expected dividend rate of 0%.
	2014 Issuances of common stock
	On June 30, 2014 we issued 267,191 shares to an accredited investor upon the conversion of a Convertible Promissory Note as discussed in Note 6.
	On June 22, 2014 we issued 125,160 shares of the Company's common stock to the holder in payment of accrued, unpaid interest under the Debenture for the period from December 23, 2013 to June 22, 2014.
	On October 24, 2014 we issued 14,286 shares of the Company's common stock to the holder in payment of accrued, unpaid interest under the Debenture for the period from December 23, 2013 to June 22, 2014.
	On December 22, 2014 we issued 117,650 shares of the Company's common stock to the holder in payment of accrued, unpaid interest under the Debenture for the period from June 23, 2014 to December 22, 2014.
	During the year ended December 31, 2014 we issued 1,850,000 shares of common stock in our 2014 unit offerings described above.
	2013 Issuances of common stock
	During the year ended December 31, 2013 we issued 685,667 shares of common stock in our 2013 unit offerings described above and 368,162 shares of common stock upon the conversion of three of the convertible bridge loans as described in Note 7.
	During the year ended December 31, 2013 we issued 48,842 shares of common stock with a fair value of $75,000 to SAM Advisors, LLC. The issuances were based on the closing market prices as of the date of issuance pursuant to our agreement to convert their $12,500 monthly consulting fee to stock at the closing market price on the last business day of each month. SAM Advisors, LLC is an entity controlled by William B. Smith, our chairman and chief executive officer.  Effective July 1, 2013 Mr. Smith receives this amount in cash.
	During the year ended December 31, 2013 we issued 6,143 shares of common stock with a fair value of $11,250 to Charles Hunt, a member of our board of directors. The issuances were based in the closing market prices as of the date of issuance pursuant to our agreement to convert $3,750 of his monthly consulting fee to stock at the closing market price on the last business day of each month.
	2012 Unit Offering Amendments
	From January 24 to November 21, 2012 we sold 474,632 units at a subscription price of $3.50 per unit for gross proceeds of $1,661,199 in our unit private placement.  Each unit consisted of one share of common stock and a three-year warrant to purchase one share of common stock at an exercise price of $3.75 per share.  A total of 474,632 shares of common stock and warrants to purchase 474,632 shares of common stock at an exercise price of $3.75 were issued.
	On October 10, 2012 the board of directors reset the exercise price of the $3.75 per share warrants to purchase 474,632 warrants issued from $3.75 per share to $2.00 per share. All other terms and conditions of the warrants remain unchanged.
	On January 25, 2013 we amended the terms of the 2012 Unit Offering, reducing the purchase price of the unit to $1.00 and reducing the exercise price of the warrant to $1.50 per share.  As a result of the amendment, the Company issued an additional 1,186,567 shares of common stock to those investors and increased the number of shares reserved for issuance upon the exercise of the warrants by 1,186,567. The issuance of the shares under the amendment was considered non-compensatory; therefore, there was no effect on the results of operations. The effect of the issuance was a reallocation of the original gross proceeds among additional paid-in capital accounts attributable to the shares and warrants, based on the relative fair values of the instruments delivered in total, including those issued under the amended terms. As a result of this reduction in price and change in the number of issued shares, the allocation of the net proceeds of $1,425,768 would have resulted in $587,989 being allocated to the warrants and the balance of the proceeds of $837,779 would have been allocated to the common stock.
	Stock issuances
	A summary of activity related to grants of common stock under the 2007 Stock Incentive Plan as of December 31, 2014 is presented below.
		Number of   Shares		Grant Date Fair Value
	Outstanding, December 31, 2012	696,329		$1.20 to $22.80
	Granted	-		-
	Forfeited	-		-
	Outstanding, December 31, 2013	696,329		$1.20 to $22.80
	Granted	-		-
	Forfeited	-		-
	Outstanding, December 31, 2014	696,329		$1.20 to $22.80
	Vested, December 31, 2014	696,329		$1.20 to $22.80
	A summary of the status of our nonvested stock grants as of December 31, 2014 and changes during the year ended December 31, 2014 is presented below.
	Nonvested Stock Grants	Number of   Shares		Weighted Average Grant Date Fair Value
	Nonvested at December 31, 2013	172,259		$                  3.26
	Granted	-		-
	Forfeited	-		-
	Vested	-172,259		3.26
	Nonvested at December 31, 2014	-		-
	There were no common stock awards from the 2007 Stock Incentive Plan for the year ended December 31, 2014.
	We made the following common stock awards for the year ended December 31, 2013 from the 2007 Stock Incentive Plan:
	On February 20, 2013 we issued 80,000 shares of restricted stock from the 2007 Stock Incentive Plan to two board members and an officer for services vesting on the date of grant.  The shares had a fair value of $128,800 based on the closing market price of our common stock on that date of $1.61 per share.
	On June 15, 2013 we issued 19,231 shares of restricted common stock to a consultant for services vesting in equal monthly installments through the one year anniversary date of service.  The shares had a fair value of $25,000 based on the closing market price of our common stock of $1.30 as of that date.
	On August 26, 2013 we issued 300,000 shares of restricted common stock to our non-executive board members and an officer for services vesting ratably through June 1, 2014.  The shares had a fair value of $360,000 based in the closing market price of $1.20 as of that date.
	We recognized a total of $207,587 and $544,889 of compensation expense related to restricted stock issuances as general and administrative and research and development expenses for the years ended December 31, 2014 and 2013, respectively.
	At December 31, 2014 there is no unrecognized compensation expense related to restricted stock grants to be recognized in future periods.
	In July, 2014 the board of directors approved the issuance of up to 83,333 three-year options to purchase common stock to two of our engineering consultants.  The options will vest immediately, and will be issued at the market price on the date of completion of certain objectives.
	Option issuances
	A summary of activity related to stock options under the 2007 Stock Incentive Plan as of December 31, 2014 is presented below.
		Number of   Shares		Exercise price range		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Outstanding, December 31, 2012	309,004		$4.60 to $20.00		$      11.62		6.0		$                 -
	Granted	317,600		$1.28 to $1.70		$        1.65
	Exercised	-		-		$            -
	Forfeited	(31,516)		$7.80 to $20.00		$      12.54
Outstanding, December 31, 2013	595,088		$1.28 to $20.00		$        6.15		3.7		$                 -
Granted	392,570		$0.70 to $0.85		$        0.73
Exercised	-		-		$            -
Forfeited	(157,722)		$4.60 to $20.00		$      10.51
Outstanding, December 31, 2014	829,936		$0.70 to $20.00		$        2.75		6.4		$        147,091
Exercisable, December 31, 2014	827,374		$0.70 to $20.00		$        2.76		6.4		$        146,829
The aggregate intrinsic value of the stock options fluctuates in relation to the market price of our common stock as reflected on the OTC Bulletin Board.
The range of exercise prices for options outstanding and options exercisable under the 2007 Stock Incentive Plan at December 31, 2014 are as follows:
Range of Exercise Prices		Weighted Average Remaining Contractual Life of Options Outstanding (in years)		Options Outstanding				Options Exercisable
				Number of   Shares		Weighted Average Exercise Price		Number of   Shares		Weighted Average Exercise Price
$0.70 to $0.85		9.3		379,412		$        0.71		378,364		$        0.71
$1.14 to $1.70		3.9		330,758		$        1.63		329,244		$        1.64
$4.60		3.0		6,250		$        4.60		6,250		$        4.60
$7.60 to $8.60		2.5		37,500		$        7.67		37,500		$        7.67
$10.20 to $13.00		5.9		40,000		$      10.97		40,000		$      10.97
$20.00		2.0		36,016		$      20.00		36,016		$      20.00
A summary of the status of our nonvested options as of December 31, 2014 and changes during the year ended December 31, 2014 is presented below.
Nonvested Options	Number of   Shares Underlying Options		Weighted Average Grant Date Fair Value
Nonvested at December 31, 2013	83,333		$                  1.70
Granted	392,570		0.73
Forfeited or expired	-		-
Vested	(473,341)		1.12
Nonvested at December 31, 2014	2,562		$                  1.02
We made the following stock option awards for the year ended December 31, 2014 from the 2007 Stock Incentive Plan:
On February 11, 2014 we issued a five-year option to purchase 13,158 shares of common stock from the Plan at an exercise price of $1.14 per share to a consultant for services.  The fair value of the option granted of $9,558 was calculated using the Black-Scholes option valuation model with the following assumptions – expected life – 5 years, risk free interest rate – 1.54%, volatility – 79.0%, and an expected dividend rate of 0%.
On May 13, 2014 we issued options to purchase 29,412 shares of common stock at an exercise price of $0.85 per share based on the closing market price of our common stock as of that date to a consultant for services. The fair value of the option granted of $16,489 was calculated using the Black-Scholes option valuation model with the following assumptions – expected life – 5 years, risk free interest rate – 1.62%, volatility – 82.8%, and an expected dividend rate of 0%.
On September 15, 2014 we issued options to purchase 350,000 shares of common stock at an exercise price of $0.70 per share based on the closing market price of our common stock as of that date to an officer and certain directors for services. The fair value of the option granted of $238,455 was calculated using the Black-Scholes option valuation model with the following assumptions – expected life – 10 years, risk free interest rate – 2.60%, volatility – 136.9%, and an expected dividend rate of 0%.
We made the following stock option awards for the year ended December 31, 2013 from the 2007 Stock Incentive Plan:
On February 20, 2013 we issued ten-year, fully vested options to purchase 42,600 shares of common stock from the 2007 Stock Incentive Plan at an exercise price of $1.61 per share to two board members and an officer for services.  The fair value of the options granted of $68,741 was calculated using the Black-Scholes option valuation model with the following assumptions – expected life – 10 years, risk free interest rate – 2.02%, volatility – 246.2%, and an expected dividend rate of 0%.
On March 11, 2013 we issued five-year options to purchase 250,000 shares of common stock at an exercise price of $1.70 per share to William B. Smith, our Chairman and Chief Executive Officer.  A total of 83,334 options vested immediately, with an additional 83,333 shares vesting on the six month and twelve month anniversary of the options.  In addition, certain performance based criteria provide for the potential acceleration of the vesting schedule.  The fair value of the options granted of $410,540 was calculated using the Black-Scholes option valuation model with the following assumptions – expected life – 5 years, risk free interest rate – 0.9%, volatility – 188.8%, and an expected dividend rate of 0%.
On November 11, 2013 we issued five-year, fully vested options to purchase 25,000 shares of common stock at an exercise price of $1.28 per share to a consultant. The fair value of the options granted of $22,055 was calculated using the Black-Scholes option valuation model with the following assumptions – expected life – 5 years, risk free interest rate – 1.47%, volatility – 88.5%, and an expected dividend rate of 0%.
We recognized compensation expense of $289,445 and $478,228 related to the vested portion of stock options based on their estimated grant date fair value as marketing expense, research and development expense or general and administrative expense based on the specific recipient of the award for the years ended December 31, 2014 and 2013, respectively.
During the year ended December 31, 2014 options to purchase 157,722 shares of common stock at a weighted average exercise price of $10.51 expired unexercised.
During the year ended December 31, 2013 options to purchase 31,516 shares of common stock at a weighted average exercise price of $14.54 expired unexercised.
At December 31, 2014, we have unrecognized compensation expense related to stock options of $1,881 which will be recognized in the first quarter of 2015.
As of December 31, 2014, the 2007 Stock Incentive Plan has 883,451 shares available for future grants of stock or options.
Warrant Issuances and Exercises
We issue new shares when warrants are exercised.  There were no warrants exercised during the years ended December 31, 2014 and 2013.
2014 Warrants
During the year ended December 31, 2014 we issued two-year warrants to purchase 680,000 shares of common stock at an exercise price of $1.25 per share in our unit offering described above.
During the year ended December 31, 2014 we issued two-year warrants to purchase 1,170,000 shares of common stock at an exercise price of $0.75 per share in our unit offering described above.
2013 Warrants
As a result of the amendment of our 2012 Unit Offering as described above, the Company issued warrants to purchase an additional 1,186,567 shares of common stock at an exercise price of $1.50 per share to the investors in the offering.
On January 25, 2013 we issued three year warrants to purchase 105,000 shares of common stock at an exercise price of $1.50 per share in our unit offering described above.
From April 9 to July 11, 2013 we issued three year warrants to purchase 580,667 shares of common stock at an exercise price of $2.00 per share in our unit offering described above.
From October 10 to December 31, 2013 we issued two-year warrants to purchase 650,000 shares of common stock at an exercise price of $1.25 per share in our unit offering described above.
In February, 2013 we issued three year warrants to purchase 368,162 shares of our common stock at an exercise price of $1.50 per share and three year warrants to purchase 98,571 shares of our common stock at an exercise price of $11.00 per share to three investors upon the conversion of convertible bridge notes as described in Note 7.
During the year ended December 31, 2013 warrants to purchase a total of 230,858 shares of common stock with a weighted average exercise price of $15.31 expired unexercised.
A summary of activity related to our warrants as of December 31, 2014 is presented below.
	Number of   Shares		Exercise price range		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)
Outstanding, December 31, 2012	2,014,120		$1.50 to $20.00		$        5.67		2.6
Granted	2,988,966		$1.25 to $11.00		$        1.86		1.8
Exercised	-		-
Forfeited	(230,858)		$7.60 to $20.00		$      15.31
Outstanding, December 31, 2013	4,772,228		$1.50 to $13.00		$        5.67		2.6
Granted	1,850,000		$0.75 to $1.25		$        0.93
Exercised	-
Forfeited	-
Outstanding, December 31, 2014	6,622,228		$0.75 to $13.00		$        2.76		1.8
Exercisable, December 31, 2014	6,622,228		$0.75 to $13.00		$        2.76		1.8
The following table summarizes our outstanding warrants as of December 31, 2014:
				Weighted-Average
Exercise		Warrants		Remaining Contractual		Number
Price		Outstanding		Life (Years)		Exercisable
$0.75		1,170,000		4.8		1,170,000
$1.25		1,330,000		1.1		1,330,000
$1.50		2,909,360		0.6		2,909,360
$2.00		580,667		1.5		580,667
$9.00		262,750		1.1		262,750
$11.00		156,071		1.9		156,071
$13.00		213,380		1.5		213,380
		6,622,228		1.6		6,622,228

Note_10_Income_Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes
Note 10 - Income Taxes	NOTE 10 - INCOME TAXES
	The net deferred tax asset is comprised of the following:
		December 31,
		2014	2013
	Net operating loss carryforwards	$  20,518,003	$  19,683,962
	Share-based compensation	946,620	1,404,983
	Valuation allowance	(21,464,623)	(21,088,945)
	Deferred income tax asset	$             -	$              -
	The provision for income taxes differs from the amount that would result from applying the federal statutory rate for the years ended December 31, 2014 and 2013 as follows:
		For the Years Ended December 31,
		2014	2013
	Net loss	$  (2,990,092)	$  (5,019,977)
	Tax at federal statutory rate (34%)	$   1,016,631	$    1,706,792
	Permanent differences	(84,192)	(631,820)
	Expiration of options and warrants	(556,761)	(764,688)
	Change in valuation allowance	(375,678)	(310,284)
	Provision for Income Taxes	$            -	$           -
	As of December 31, 2014, we had net operating loss carryforwards for U.S. federal income tax reporting purposes which if unused, will expire in the following years:
		US
	Year	Amount
	2018	$     27,080,269
	2019	1,745,867
	2020	6,137,725
	2021	5,251,175
	2022	1,751,322
	2023	78,281
	2024	413,886
	2025	508,429
	2026	465,173
	2027	760,272
	2028	2,494,690
	2029	2,121,595
	2030	1,688,397
	2031	2,433,302
	2032	2,911,306
	2033	2,052,317
	2034	2,453,062
		$   60,347,068
	The utilization of U.S. net operating loss carryforwards may be limited due to the ownership change under the provisions of Internal Revenue Code Section 382. The fiscal years 2010 to 2014 remain open to examination to U.S. Federal authorities and other jurisdictions in the U.S. where we operate.

Note_11_Sendio_Sro_Insolvency

Note 11 - Sendio, Sro Insolvency	12 Months Ended
	Dec. 31, 2014
Notes
Note 11 - Sendio, Sro Insolvency	NOTE 11 – SENDIO, SRO INSOLVENCY
	On February 13, 2012, Sendio filed a petition of insolvency with the Regional Court in Olomouc, Czech Republic.  In March, 2012 the court determined that Sendio was insolvent, and control of the legal entity passed to a court appointed trustee. The trustee is overseeing the orderly sale of the assets and using any proceeds to satisfy the liabilities of Sendio.  Included in the balance sheets are the following liabilities of Sendio that are subject to the insolvency proceedings:
		December 31,
		2014	2013
	Current liabilities:
	Accounts payable	$        189,089	$        189,089
	Accrued payroll	357,052	357,052
	Capital lease obligation, current portion	9,313	9,313
	Total liabilities of Sendio	555,454	555,454

Note_12_Subsequent_Events

Note 12 - Subsequent Events	12 Months Ended
	Dec. 31, 2014
Notes
Note 12 - Subsequent Events	NOTE 12 – SUBSEQUENT EVENTS
	Effective January 20, 2015 the holders of the Notes under the Loan Agreement dated December 20, 2012 as discussed in Note 8 converted $100,000 of principal and $427,031 of accrued interest under the Notes into an aggregate of 702,709 shares of common stock and three year warrants to purchase 702,709 shares of common stock at an exercise price of $1.00 per share.  The Company will recognize the loss on conversion in the first quarter of 2015.
	Through April 16, 2015 we received gross proceeds of $260,000 from accredited investors at a price of $0.50 per unit and issued 520,000 shares of common stock and two-year warrants to purchase 150,000 shares of common stock at an exercise price of $0.75 per share.
	On February 10, 2015 we amended our unit offering to extend the $0.75 warrants issued in conjunction with the units sold to five years.  In addition, the investors in the offering were granted a down-round protection right to receive additional shares of common stock if any issuance under an offering for the next two years is made by the Company at less than $0.50 per share. In the event of this occurring, the investors will be issued additional shares of common stock at a price equivalent to the offering made at that time.  The Company will account for this in the first quarter of 2015.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies: Principles of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of Vu1 and all of its wholly-owned and controlled subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents
	For purposes of the statements of cash flows, we consider all investments purchased with original maturities of three months or less to be cash equivalents. At December 31, 2014 we have no cash in excess of federal insurance limits.

Note_2_Summary_of_Significant_4

Note 2 - Summary of Significant Accounting Policies: Equipment (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Equipment	Equipment
	Equipment is comprised of equipment used in the testing and development of the manufacturing process for our lighting products and is stated at cost. We provide for depreciation using the straight-line method over the estimated useful lives of three to five years. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains or losses on the sale of equipment are reflected in the statements of operations.

Note_2_Summary_of_Significant_5

Note 2 - Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Income Taxes	Income Taxes
	We recognize the amount of income taxes payable or refundable for the current year and recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement amounts of certain assets and liabilities and their respective tax bases. Deferred tax assets and deferred tax liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled. A valuation allowance is required when it is less likely than not that we will be able to realize all or a portion of our deferred tax assets.
	FASB ASC 740-10-25 clarifies the accounting for uncertain tax positions and requires that an entity recognizes in the consolidated financial statements the impact of a tax position, if that position is more likely than not of being sustained upon examination, based on the technical merits of the position.  Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized tax benefits, if and when required, as part of income tax expense in the consolidated statements of operations.

Note_2_Summary_of_Significant_6

Note 2 - Summary of Significant Accounting Policies: Long-lived Assets (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Long-lived Assets	Long-Lived Assets
	Long-lived assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.  Management reviewed the assets at December 31, 2014 and determined there was no impairment.

Note_2_Summary_of_Significant_7

Note 2 - Summary of Significant Accounting Policies: Fair Value Measurements (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Fair Value Measurements	Fair Value of Financial Instruments
	Financial instruments consist of cash, payables and accrued liabilities, loans payable, bridge loans, judgment payable and convertible debentures. The fair value of our cash, receivables, payables and accrued liabilities, judgment payable and loans payable  are carried at historical cost; their respective estimated fair values approximate their carrying values due to the short term nature of these items. It is not practical to determine the fair value of our convertible debentures due to the unique terms and embedded financial instruments.
	Derivative financial instruments, as defined in ASC 815 “Accounting for Derivative Financial Instruments and Hedging Activities” consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g., interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. We generally do not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks.
	Fair Value Measurements
	ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. This hierarchy prioritizes the inputs into three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Significant fair value measurements resulted from the application of ASC 815 to our convertible promissory note and warrant financing arrangements and ASC 718-10 for our share-based payment arrangements.

Note_2_Summary_of_Significant_8

Note 2 - Summary of Significant Accounting Policies: Non-controlling Interest (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Non-controlling Interest	Non-Controlling Interest
	Non-controlling interest represents the equity of the 33.3%

Note_2_Summary_of_Significant_9

Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Revenue Recognition	Revenue Recognition
	Revenues are recognized when (a) persuasive evidence of an arrangement exists, (b) delivery has occurred and no significant obligations remain, (c) the fee is fixed or determinable and (d) collection is determined to be probable.

Recovered_Sheet1

Note 2 - Summary of Significant Accounting Policies: Research and Development Costs (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Research and Development Costs	Research and Development Costs
	For financial reporting purposes, all costs of research and development activities performed internally or on a contract basis are expensed as incurred. For the years ended December 31, 2014 and 2013, research and development expenses were comprised primarily of technical consulting expenses, overheads, travel and operational costs related to the development of production.

Recovered_Sheet2

Note 2 - Summary of Significant Accounting Policies: Share-based Payments (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Share-based Payments	Share-Based Payments
	We account for share-based compensation expense to reflect the fair value of share-based awards measured at the grant date.  This expense is recognized over the requisite service period and is adjusted each period for anticipated forfeitures. We estimate the fair value of each share-based award on the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model incorporates assumptions as to stock price volatility, the expected life of options, a risk-free interest rate and dividend yield. On October 26, 2007 our Board of Directors approved the Vu1 Corporation 2007 Stock Incentive Plan (the “Stock Incentive Plan”).  A total of 500,000 shares of our common stock were authorized for issuance under the Stock Incentive Plan.  The Stock Incentive Plan was approved by our stockholders on May 22, 2008. On March 14, 2011, our Board of Directors increased the number of shares of our common stock that we are authorized to issue under our Stock Incentive Plan from 500,000 shares to 1,000,000 shares.  A majority of our stockholders approved the amendment to the Stock Incentive Plan on October 10, 2011. On August 26, 2013 the board of directors increased the number of shares authorized for issuance under the 2007 Stock Incentive Plan by 1,500,000 shares to a total of 2,500,000 shares. See Note 9.

Recovered_Sheet3

Note 2 - Summary of Significant Accounting Policies: Loss Per Share (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Loss Per Share	Loss Per Share
	We calculate basic loss per share by dividing loss available to common stockholders by the weighted-average number of shares of common stock outstanding, excluding unvested stock. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common shares, including unvested stock, had been issued and if the additional common shares were dilutive.
	The following potentially dilutive common shares are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to our net losses:
		Year ended December 31,
		2014	2013
	Warrants	6,622,228	4,772,228
	Convertible debt	1,304,631	1,152,223
	Stock options	829,936	595,088
	Unvested stock	-	319,231
	Total potentially dilutive securities	8,756,795	6,838,770

Recovered_Sheet4

Note 2 - Summary of Significant Accounting Policies: Recently Announced Accounting Standards (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Recently Announced Accounting Standards	Recently Announced Accounting Standards – In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. ASU 2014-09 will be effective for the Company’s fiscal year beginning January 1, 2017, with early application not permitted. The Company does not anticipate the adoption of ASU 2014-09 will have a material impact on its financial statements and related disclosures.
	In June 2014, the FASB issued ASU 2014-12, Compensation-Stock Compensation (Topic 718). The ASU clarifies how entities should treat performance targets that can be achieved after the requisite service period of a share-based payment award. The accounting standard is effective for interim and annual periods beginning December 15, 2015.  The Company does not anticipate the adoption of ASU 2014-12 will have a material impact on its financial statements and related disclosures.
	Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company’s financial position, result of operations or cash flows.

Recovered_Sheet5

Note 2 - Summary of Significant Accounting Policies: Loss Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
		Year ended December 31,
		2014	2013
	Warrants	6,622,228	4,772,228
	Convertible debt	1,304,631	1,152,223
	Stock options	829,936	595,088
	Unvested stock	-	319,231
	Total potentially dilutive securities	8,756,795	6,838,770

Note_6_Convertible_Debentures_

Note 6 - Convertible Debentures: Schedule of Carrying Values of Convertible Debentures (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Carrying Values of Convertible Debentures
		31-Dec-14	31-Dec-13
	Debentures Due June 22, 2013, in default, interest at 18%	$            235,300	$         1,352,975
	Debentures Due June 22, 2015, interest at 10%	2,553,000	2,553,000
	Carrying value	$        2,788,300	$        3,905,975

Note_6_Convertible_Debentures_1

Note 6 - Convertible Debentures: Schedule Of Interest Expense Convertible Debentures (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule Of Interest Expense Convertible Debentures
		Year ended December 31,
		2014	2013
	Amortization of original issue discount	$                            -	$               155,443
	Amortization of beneficial conversion feature and warrant allocation	-	415,811
	Amortization of loan costs	-	104,392
	Penalty interest payable in cash	-	144,121
	Stated interest payable in cash	394,395	259,168
		$                  394,395	$             1,078,935

Note_8_Loans_Payable_Schedule_

Note 8 - Loans Payable: Schedule of maturities of debt (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of maturities of debt		31-Dec-14
	2015	2,888,300
		$       2,888,300

Note_9_Stockholders_Equity_Sum

Note 9 - Stockholders' Equity: Summary of Activity Related To Grants of Common Stock Under The 2007 Stock Incentive Plan (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Summary of Activity Related To Grants of Common Stock Under The 2007 Stock Incentive Plan
		Number of   Shares	Grant Date Fair Value
	Outstanding, December 31, 2012	696,329	$1.20 to $22.80
	Granted	-	-
	Forfeited	-	-
	Outstanding, December 31, 2013	696,329	$1.20 to $22.80
	Granted	-	-
	Forfeited	-	-
	Outstanding, December 31, 2014	696,329	$1.20 to $22.80
	Vested, December 31, 2014	696,329	$1.20 to $22.80

Note_9_Stockholders_Equity_Sch

Note 9 - Stockholders' Equity: Schedule of Nonvested Share Activity (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Nonvested Share Activity
	Nonvested Stock Grants	Number of   Shares	Weighted Average Grant Date Fair Value
	Nonvested at December 31, 2013	172,259	$                  3.26
	Granted	-	-
	Forfeited	-	-
	Vested	-172,259	3.26
	Nonvested at December 31, 2014	-	-

Note_9_Stockholders_Equity_Sch1

Note 9 - Stockholders' Equity: Schedule of Share-based Compensation, Stock Options, Activity (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Share-based Compensation, Stock Options, Activity
		Number of   Shares	Exercise price range	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
	Outstanding, December 31, 2012	309,004	$4.60 to $20.00	$      11.62	6.0	$                 -
	Granted	317,600	$1.28 to $1.70	$        1.65
	Exercised	-	-	$            -
	Forfeited	(31,516)	$7.80 to $20.00	$      12.54
	Outstanding, December 31, 2013	595,088	$1.28 to $20.00	$        6.15	3.7	$                 -
	Granted	392,570	$0.70 to $0.85	$        0.73
	Exercised	-	-	$            -
	Forfeited	(157,722)	$4.60 to $20.00	$      10.51
	Outstanding, December 31, 2014	829,936	$0.70 to $20.00	$        2.75	6.4	$        147,091
	Exercisable, December 31, 2014	827,374	$0.70 to $20.00	$        2.76	6.4	$        146,829

Note_9_Stockholders_Equity_Sch2

Note 9 - Stockholders' Equity: Schedule of exercise prices for options outstanding and exercisable (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of exercise prices for options outstanding and exercisable
	Range of Exercise Prices	Weighted Average Remaining Contractual Life of Options Outstanding (in years)	Options Outstanding		Options Exercisable
			Number of   Shares	Weighted Average Exercise Price	Number of   Shares	Weighted Average Exercise Price
	$0.70 to $0.85	9.3	379,412	$        0.71	378,364	$        0.71
	$1.14 to $1.70	3.9	330,758	$        1.63	329,244	$        1.64
	$4.60	3.0	6,250	$        4.60	6,250	$        4.60
	$7.60 to $8.60	2.5	37,500	$        7.67	37,500	$        7.67
	$10.20 to $13.00	5.9	40,000	$      10.97	40,000	$      10.97
	$20.00	2.0	36,016	$      20.00	36,016	$      20.00

Note_9_Stockholders_Equity_Sch3

Note 9 - Stockholders' Equity: Schedule of nonvested options (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of nonvested options
	Nonvested Options	Number of   Shares Underlying Options	Weighted Average Grant Date Fair Value
	Nonvested at December 31, 2013	83,333	$                  1.70
	Granted	392,570	0.73
	Forfeited or expired	-	-
	Vested	(473,341)	1.12
	Nonvested at December 31, 2014	2,562	$                  1.02

Note_9_Stockholders_Equity_Sch4

Note 9 - Stockholders' Equity: Schedule of warrant activity (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of warrant activity
		Number of   Shares	Exercise price range	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)
	Outstanding, December 31, 2012	2,014,120	$1.50 to $20.00	$        5.67	2.6
	Granted	2,988,966	$1.25 to $11.00	$        1.86	1.8
	Exercised	-	-
	Forfeited	(230,858)	$7.60 to $20.00	$      15.31
	Outstanding, December 31, 2013	4,772,228	$1.50 to $13.00	$        5.67	2.6
	Granted	1,850,000	$0.75 to $1.25	$        0.93
	Exercised	-
	Forfeited	-
	Outstanding, December 31, 2014	6,622,228	$0.75 to $13.00	$        2.76	1.8
	Exercisable, December 31, 2014	6,622,228	$0.75 to $13.00	$        2.76	1.8

Note_9_Stockholders_Equity_Sch5

Note 9 - Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Stockholders' Equity Note, Warrants or Rights
			Weighted-Average
	Exercise	Warrants	Remaining Contractual	Number
	Price	Outstanding	Life (Years)	Exercisable
	$0.75	1,170,000	4.8	1,170,000
	$1.25	1,330,000	1.1	1,330,000
	$1.50	2,909,360	0.6	2,909,360
	$2.00	580,667	1.5	580,667
	$9.00	262,750	1.1	262,750
	$11.00	156,071	1.9	156,071
	$13.00	213,380	1.5	213,380
		6,622,228	1.6	6,622,228

Note_10_Income_Taxes_Schedule_

Note 10 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities
		December 31,
		2014	2013
	Net operating loss carryforwards	$  20,518,003	$  19,683,962
	Share-based compensation	946,620	1,404,983
	Valuation allowance	(21,464,623)	(21,088,945)
	Deferred income tax asset	$             -	$              -

Note_10_Income_Taxes_Schedule_1

Note 10 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation
		For the Years Ended December 31,
		2014	2013
	Net loss	$  (2,990,092)	$  (5,019,977)
	Tax at federal statutory rate (34%)	$   1,016,631	$    1,706,792
	Permanent differences	(84,192)	(631,820)
	Expiration of options and warrants	(556,761)	(764,688)
	Change in valuation allowance	(375,678)	(310,284)
	Provision for Income Taxes	$            -	$           -

Note_10_Income_Taxes_Summary_o

Note 10 - Income Taxes: Summary of Tax Credit Carryforwards (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Summary of Tax Credit Carryforwards
		US
	Year	Amount
	2018	$     27,080,269
	2019	1,745,867
	2020	6,137,725
	2021	5,251,175
	2022	1,751,322
	2023	78,281
	2024	413,886
	2025	508,429
	2026	465,173
	2027	760,272
	2028	2,494,690
	2029	2,121,595
	2030	1,688,397
	2031	2,433,302
	2032	2,911,306
	2033	2,052,317
	2034	2,453,062
		$   60,347,068

Note_11_Sendio_Sro_Insolvency_

Note 11 - Sendio, Sro Insolvency: assets and liabilities of Sendio that are subject to the insolvency proceedings (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
assets and liabilities of Sendio that are subject to the insolvency proceedings
		December 31,
		2014	2013
	Current liabilities:
	Accounts payable	$        189,089	$        189,089
	Accrued payroll	357,052	357,052
	Capital lease obligation, current portion	9,313	9,313
	Total liabilities of Sendio	555,454	555,454

Note_1_Business_and_Organizati1

Note 1 - Business and Organization (Details)	12 Months Ended
	Dec. 31, 2014
Details
Cumulative Percentage of Ownership	66.67%

Recovered_Sheet6

Note 2 - Summary of Significant Accounting Policies: Non-controlling Interest (Details)	Dec. 31, 2014
Details
Non-controlling Interest, Telisar Corporation	33.30%

Recovered_Sheet7

Note 2 - Summary of Significant Accounting Policies: Loss Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,756,795	6,838,770
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,622,228	4,772,228
Convertible Debt Securities
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,304,631	1,152,223
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	829,936	595,088
Unvested Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		319,231

Note_3_Going_Concern_Matters_D

Note 3 - Going Concern Matters (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Net loss	$2,990,092	$5,019,977
Net cash flows from operating activities	1,081,190	1,716,606
Accumulated deficit	$91,416,708	$88,426,616

Note_4_Related_Party_Transacti1

Note 4 - Related Party Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Sam Advisors
Issued Shares	48,842
Common Stock Fair Value	$75,000
Converted Consulting Fees	12,500
CharlesHuntMember
Issued Shares	6,143
Common Stock Fair Value	11,250
Converted Consulting Fees	$3,750

Note_5_Commitments_and_Conting1

Note 5 - Commitments and Contingencies: Judgments Payable (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Payment on judgment payable	$132,876
Judgment payable	1,295,920
Judgment 1
Payment on judgment payable	132,876
Judgment payable	132,876
Judgment payable principle	117,650
Judgment payable interest	14,619
Judgment 2
Judgment payable	705,900
Judgement payable interest	218,215
Judgment 3
Judgment payable	294,125
Judgement payable interest	$77,680

Note_5_Commitments_and_Conting2

Note 5 - Commitments and Contingencies: Operating Leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 18, 2012
Details
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year	$60,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two	5,000
Operating Lease Monthly Payments			2,035
Rent Expense	$55,000	$24,647

Note_6_Convertible_Debentures_2

Note 6 - Convertible Debentures (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2011	Oct. 10, 2012	Jun. 22, 2011
Class of Warrant or Right, Exercise Price of Warrants or Rights			$3.75
ConvertibleDebenturesMember
Proceeds from issuance of convertible notes payable and warrants		$3,500,000
Debenture Issue Price Percentage		85.00%
Conversion Price per Share				$11
Limit on Beneficial Ownership as a Percentage of Outstanding Shares				4.99%
Debt Securities Default Condition Monetary Limit	$150,000
Assets Disposal Percentage	50.00%
Warrants Issued in Conjunction with Convertible Debentures	187,175
Class of Warrant or Right, Exercise Price of Warrants or Rights				$13

Note_6_Convertible_Debentures_3

Note 6 - Convertible Debentures: Schedule of Carrying Values of Convertible Debentures (Details) (USD $)	Dec. 31, 2014		Dec. 31, 2013
Carrying value	$2,788,300		$3,905,975
DebenturesDueJune222013Member
Face amount	235,300	[1]	1,352,975	[1]
DebenturesDueJune232014Member
Face amount	$2,553,000	[2]	$2,553,000	[2]
[1]	Interest at 18%
[2]	Interest at 10%

Note_6_Convertible_Debentures_4

Note 6 - Convertible Debentures: Schedule Of Interest Expense Convertible Debentures (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Amortization of original issue discount		$155,443
Amortization of beneficial conversion feature and warrant allocation		415,811
Amortization of loan costs		104,392
Penalty Interest Payable in Cash		144,121
Stated Interest Payable in Cash	394,395	259,168
Interest Expense Related to Convertible Debentures	$394,395	$1,078,935

Note_7_Convertible_Bridge_Loan1

Note 7 - Convertible Bridge Loans (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Oct. 10, 2012	Dec. 31, 2014	Jan. 31, 2013
Class of Warrant or Right, Exercise Price of Warrants or Rights			$3.75
Mark W Weber
Proceeds from issuance of bridge notes	$50,000
ConvertibleBridgeLoans1Member
Proceeds from issuance of bridge notes	475,000
Debt Instrument, Interest Rate, Effective Percentage	12.00%
Debt Instrument, Convertible, Interest Expense		7,027
Class of Warrant or Right, Exercise Price of Warrants or Rights				$11	$1.50
Debt Conversion, Converted Instrument, Amount		368,162
Accrued Interest and Loan Fees Included in Conversion		68,162
Debt Conversion Converted Instrument Units Issued One		368,162
Debt Conversion Converted Instrument Units Issued Two		98,571
Class of Warrant or Right, Exercise Price of Warrants or Rights, Two		$11
Fair Value of Common Stock		662,690
Fair Value of Three Year Warrants, One		$633,121
Expected life (years)		3 years
Risk-free interest rate		0.82%
Estimated volatility		227.10%
Expected Dividend Rate		0.00%

Note_8_Loans_Payable_Details

Note 8 - Loans Payable (Details) (USD $)	12 Months Ended		9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 20, 2012
Interest expense	$831,292	$1,191,786
ProceedsFromConvertibleBridgeLoan	132,876
Conversion feature convertible into common stock	265,751
Amortization of beneficial conversion feature	95,671
Accrued interest related to conversion feature	1,325
Proceeds from loan payable	132,876	100,000
December202012LoanPayableMember
Proceeds From Loan Agreement					100,000
Interest expense			339,900	81,714
Loan Cost Amortization			0	23,514
Default Interest rate	109.50%
StatedInterestRateMember
Interest expense	1,325
ConvertibleDebenturesMember
Interest expense	$95,671

Note_8_Loans_Payable_Schedule_1

Note 8 - Loans Payable: Schedule of maturities of debt (Details) (USD $)	Dec. 31, 2014
Details
2015	$2,888,300
Total convertible bridge loans	$2,888,300

Note_9_Stockholders_Equity_Pre

Note 9 - Stockholders' Equity: Preferred Stock (Details)	Dec. 31, 2014	Dec. 31, 2013
Details
Preferred stock shares authorized	10,000,000	10,000,000

Note_9_Stockholders_Equity_201

Note 9 - Stockholders' Equity: 2014 Unit Offering (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Issuance of units of stock and warrants for cash	$1,265,000	$1,503,465
Common Stock
Issuance of units of stock and warrants for cash	1,265,000	1,503,465
Issuance of units of stock and warrants for cash - Shares	1,850,000	1,262,334
Common Stock | 2014 Unit Offering 1
Issuance of units of stock and warrants for cash	680,000
Issuance of units of stock and warrants for cash - Shares	680,000
Common Stock | 2014 Unit Offering 2
Issuance of units of stock and warrants for cash	$585,000
Issuance of units of stock and warrants for cash - Shares	1,170,000

Note_9_Stockholders_Equity_2011

Note 9 - Stockholders' Equity: 2013 Unit Offering (Details) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2013
Proceeds raised from accredited investors	$650,000	$871,000
Converted Loan Conversion Price	$1	$1.50
Converted Loan Amount		110,000
Proceeds from board of directors		10,000
Aggregate shares issued		580,667
Exercise Price		$2
Net proceeds raised	650,000	761,000
Fair Value Allocated to warrants	256,836	256,836
Fair Value Allocated to common stock	504,164	504,164
N2013UnitOfferingMember
Restricted Shares To Accredited Investors			105,000
Purchase Price			$1
Proceeds From Restricted Shares To Accredited Investors			105,000
Issuance Of Three Year Warrants			105,000
Warrant Exercise Price			$1.50
Proceeds Allocated To Warrants			52,363
Proceeds Allocated To Common Stock			$52,637
Expected life (years)			3 years
Risk-free interest rate			0.42%
Estimated volatility			346.40%
Expected Dividend Rate			0.00%
CommonStockAndWarrantsMember
Expected life (years)		3 years
Risk-free interest rate		0.34%
Estimated volatility		91.40%
Expected Dividend Rate		0.00%

Note_9_Stockholders_Equity_2012

Note 9 - Stockholders' Equity: 2014 Issuances of common stock (Details) (Common Stock)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Bridge Loan and Interest Conversion - Shares	267,191
Interest converted to stock - Shares	257,096
Issuance of units of stock and warrants for cash - Shares	1,850,000	1,262,334
2014 Unit Offering 1
Interest converted to stock - Shares	125,160
Issuance of units of stock and warrants for cash - Shares	680,000
2014 Unit Offering 2
Interest converted to stock - Shares	14,286
Issuance of units of stock and warrants for cash - Shares	1,170,000
2014 Unit Offering 3
Interest converted to stock - Shares	117,650

Note_9_Stockholders_Equity_2013

Note 9 - Stockholders' Equity: 2013 Issuances of common stock (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Shares Issued in Unit Offering	685,667
Sam Advisors
Issuance Of Common Shares	48,842
Common Stock Fair Value	75,000
Converted Consulting Fees	12,500
CharlesHuntMember
Issuance Of Common Shares	6,143
Common Stock Fair Value	11,250
Converted Consulting Fees	3,750
ConvertibleBridgeLoans1Member
Bridge Loan Converted Into Shares Of Restricted Common Stock	368,162

Note_9_Stockholders_Equity_2014

Note 9 - Stockholders' Equity: 2012 Unit Offering Amendments (Details) (USD $)	10 Months Ended	12 Months Ended
	Nov. 21, 2012	Dec. 31, 2013	Jan. 25, 2013	Oct. 10, 2012	Dec. 31, 2014
PrivatePlacementUnitsSold	474,632
Unit Subscription Price	$3.50
Proceeds from Issuance of Private Placement	$1,661,199
Class of Warrant or Right, Exercise Price of Warrants or Rights				$3.75
Shares Issued in Unit Offering		685,667
Aggregate Warrants Outstanding				474,632
Exercise Price of Warrants Subsequent to Reset			$1.50	$2
Purchase Price Of Unit Subsequent To Reset			$1
CommonStock1Member
Class of Warrant or Right, Exercise Price of Warrants or Rights					$3.75
Shares Issued in Unit Offering	474,632
Warrants Issued in Unit Offering	474,632

Note_9_Stockholders_Equity_Sum1

Note 9 - Stockholders' Equity: Summary of Activity Related To Grants of Common Stock Under The 2007 Stock Incentive Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	696,329	696,329	696,329
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	696,329
Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	1.2	1.2	1.2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	1.2
Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	22.8	22.8	22.8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	22.8

Note_9_Stockholders_Equity_Sch6

Note 9 - Stockholders' Equity: Schedule of Nonvested Share Activity (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Details
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		172,259
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value		$3.26
Sharebased Compensation Arrangement By Sharebased Payment Award Options, Nonvested Number Of Shares Vested	-172,259
Sharebased Compensation Arrangement By Sharebased Payment Award Options, Nonvested Options Vested Weighted Average Grant Date Fair Value	$3.26

Note_9_Stockholders_Equity_Det

Note 9 - Stockholders' Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Allocated Share-based Compensation Expense	$207,587	$544,889
Compensation Expense related to the vested portion of stock options	289,445	478,228
Compensation Expense, unrecognized	$1,881

Note_9_Stockholders_Equity_Sch7

Note 9 - Stockholders' Equity: Schedule of warrant activity (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrants Outstanding	6,622,228	4,772,228	2,014,120
Warrants Outstanding Weighted Average Exercise Price	$2.76	$5.67	$5.67
Warrants Outstanding Weighted Average Remaining Contractual Term (Years)	1.8	2.6	2.6
Warrants Granted	1,850,000	2,988,966
Warrants Granted Weighted Average Exercise Price	$0.93	$1.86
Warrants Granted Weighted Average Remaining Contractual Term (Years)		1.8
Warrants Forfeited		-230,858
Warrants Forfeited Weighted Average Exercise Price		$15.31
Warrants Exercisable	6,622,228
Warrants Exercisable Weighted Average Exercise Price	$2.76
Warrants Exercisable Weighted Average Remaining Contractual Term (Years)	1.8
Minimum
Warrants Outstanding Exercise Price	$0.75	$1.50	$1.50
Warrants Granted Exercise Price	$0.75	$1.25
Warrants Forfeited Exercise Price		$7.60
Warrants Exercisable Exercise Price	$0.75
Maximum
Warrants Outstanding Exercise Price	$13	$13	$20
Warrants Granted Exercise Price	$1.25	$11
Warrants Forfeited Exercise Price		$20
Warrants Exercisable Exercise Price	$13

Note_9_Stockholders_Equity_Sch8

Note 9 - Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Details)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrants Outstanding	6,622,228	4,772,228	2,014,120
Weighted - Average Remaining Contractual Life (Years)	1.6
Warrants Exercisable	6,622,228
Warrant One
Exercise Price, Warrants	0.75
Warrants Outstanding	1,170,000
Weighted - Average Remaining Contractual Life (Years)	4.8
Warrants Exercisable	1,170,000
Warrant Two
Exercise Price, Warrants	1.25
Warrants Outstanding	1,330,000
Weighted - Average Remaining Contractual Life (Years)	1.1
Warrants Exercisable	1,330,000
Warrant Three
Exercise Price, Warrants	1.5
Warrants Outstanding	2,909,360
Weighted - Average Remaining Contractual Life (Years)	0.6
Warrants Exercisable	2,909,360
Warrant Four
Exercise Price, Warrants	2
Warrants Outstanding	580,667
Weighted - Average Remaining Contractual Life (Years)	1.5
Warrants Exercisable	580,667
Warrant Five
Exercise Price, Warrants	9
Warrants Outstanding	262,750
Weighted - Average Remaining Contractual Life (Years)	1.1
Warrants Exercisable	262,750
Warrant Six
Exercise Price, Warrants	11
Warrants Outstanding	156,071
Weighted - Average Remaining Contractual Life (Years)	1.9
Warrants Exercisable	156,071
WarrantSevenMember
Exercise Price, Warrants	13
Warrants Outstanding	213,380
Weighted - Average Remaining Contractual Life (Years)	1.5
Warrants Exercisable	213,380

Note_10_Income_Taxes_Schedule_2

Note 10 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Details
Deferred Tax Assets, Operating Loss Carryforwards	$20,518,003	$19,683,962
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	946,620	1,404,983
Deferred Tax Assets, Valuation Allowance	($21,464,623)	($21,088,945)

Note_10_Income_Taxes_Schedule_3

Note 10 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Loss before provision for income taxes	($2,990,092)	($5,019,977)
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	1,016,631	1,706,792
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount	-84,192	-631,820
Expiration of options and warrants	-556,761	-764,688
Valuation Allowance, Deferred Tax Asset, Change in Amount	-375,678	-310,284
Provision for income taxes

Note_10_Income_Taxes_Summary_o1

Note 10 - Income Taxes: Summary of Tax Credit Carryforwards (Details) (USD $)	Dec. 31, 2014
Tax Credit Carryforward, Amount	$60,347,068
2018
Tax Credit Carryforward, Amount	27,080,269
2019
Tax Credit Carryforward, Amount	1,745,867
2020
Tax Credit Carryforward, Amount	6,137,725
2021
Tax Credit Carryforward, Amount	5,251,175
2022
Tax Credit Carryforward, Amount	1,751,322
2023
Tax Credit Carryforward, Amount	78,281
2024
Tax Credit Carryforward, Amount	413,886
2025
Tax Credit Carryforward, Amount	508,429
2026
Tax Credit Carryforward, Amount	465,173
2027
Tax Credit Carryforward, Amount	760,272
2028
Tax Credit Carryforward, Amount	2,494,690
2029
Tax Credit Carryforward, Amount	2,121,595
2030
Tax Credit Carryforward, Amount	1,688,397
2031
Tax Credit Carryforward, Amount	2,433,302
2032
Tax Credit Carryforward, Amount	2,911,306
2033
Tax Credit Carryforward, Amount	2,052,317
2034
Tax Credit Carryforward, Amount	$2,453,062

Note_11_Sendio_Sro_Insolvency_1

Note 11 - Sendio, Sro Insolvency: assets and liabilities of Sendio that are subject to the insolvency proceedings (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued payroll	$192,725	$192,725
Total current liabilities	6,874,392	6,227,053
Sendio
Accounts Payable, Current	189,089	189,089
Accrued payroll	357,052	357,052
Capital lease obligation, current portion	9,313	9,313
Total current liabilities	$555,454	$555,454